Coronary spasm induced by capecitabine by Schnetzler, B. et al.
Annals of Oncology 12: 723-725, 2001.
Letters to the editor
Will the sentinel lymph node (SLN)
stand a second time - SLN biopsy in
breast cancer patients with isolated
local recurrence following breast
conserving therapy and previous
SLN procedure
The axillary lymph node status remains one of the most
important independent prognostic factors providing signifi-
cant information for accurate staging and determination of
adjuvant therapy. To avoid axillary lymph node dissection
(ALND) in clinically node negative patients, sentinel lymph
node (SLN) biopsy was proposed as an alternative to ALND,
thus minimizing possible post-operative complication (e.g.,
lymphedema, dysaesthesia, etc).
As a consequence of the frequent application of SLN biopsy,
especially when it becomes adopted as standard treatment, a
new group of breast cancer patients will emerge in the near
future. Characteristics of these patients are that they were
treated conservatively, had a SLN biopsy, and on finding an
uninvolved sentinel node, ALND was consequently omitted.
In the case of an isolated local recurrence in these patients
the question arises whether a re-staging of the axillary lymph
node status - especially if the axilla is clinically unsuspicious -
is of importance and how it should be performed.
Data from previous studies showed that, depending on the
stage of the disease and the treatment given, between 10% and
35% of patients experience an isolated locoregional recurrence
(LRR) [1-3]. About 80% of these recurrences happen during
the first two years after primary treatment [4]. For the above
characterized group the estimated risk will be about 15%—20%.
For patients who had Breast Conserving Treatment (BCT)
before the SLN era, treatment options for an isolated local
recurrence (e.g., no overt evidence of distant metastases)
encompasses local excision or simple mastectomy only, because
the axillary lymph nodes were already dissected at the time of
the first operation.
For this new group of patients in whom axillary lymph nodes
were not dissected the situation is quite different. Clinically
involved axillary lymph nodes are a clear indication to perform
ALND.
Until now, there are no guidelines on how to proceed in a
clinically unsuspicious axilla. One of the options could be to
perform ALND routinely, mainly for re-staging reasons.
In this context the question arises whether a SLN biopsy is
feasible a second time and, moreover, whether it is reliable in
predicting the axillary lymph node status.
We would suggest that the issues above should be inves-
tigated in the frame of a properly conducted clinical trial for
the following reasons:
First, there is logical concern that the first SLN biopsy and
eventually radiotherapy to the breast including skin, etc., might
impair the sentinel lymph node mapping. However, if the SLN
is defined as a first lymph node draining from the tumor-
bearing area it is to be expected that in most patients an
identification as well as the consecutive removal of this 'second'
SLN should be possible.
Furthermore, the predictive value of the axillary lymph
node status of this 'second' SLN should be examined.
Finally, the subgroup of patients in which a second SLN
biopsy procedure might be beneficial should be defined.
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Coronary spasm induced by
capecitabine
We would like to report a case of coronary vasospasm most
likely following oral capecitabine administration.
A 63-year-old female with a history of moderate arterial
hypertension was diagnosed in June 2000 with breast carci-
noma. A tumorectomy with axillary lymphnode dissection was
performed. Although 5 out of 10 lymph nodes were metastatic
and the tumor cells failed to express steroid receptors, she
declined adjuvant chemotherapy and was treated by radio-
therapy. Four months after the diagnosis, she developed bone
and liver metastases which prompted the administration of
vinorelbine (25 mg/m2) and capecitabine (1500 mg/m2).
Forty-eight hours after the introduction of chemotherapy, the
patient developed typical angina pectoris at rest. The ECG
showed ST-segment elevation in leads DI, aVL, V5 and V6.
There was no pericardia! friction rub. Echocardiography was
normal.
Initially, chest pain and ECG changes responded to intra-
venous nitrates. However, recurrent angina required the addition
of intravenous heparin, acetylsalicylic acid and betablockers.
Troponin levels remained in the normal range. The persistence
of clinical and electrocardiographic signs of angina, justified a
coronary angiogram which revealed normal coronary arteries
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and an adequate left ventricular function. A coronary spasm
secondary to capecitabin was suspected. The last dose of the
drug was given the morning of the coronary angiogram. The
patient presented a new chest pain episode a few hours after the
coronary angiogram. Betablockers were stopped and calcium-
blockers were introduced. Since then, the patient has not
presented any chest pain.
Cardiotoxicity is a recognized side effect of 5-fluorouracil
(5-FU), a related fiuorinated pyrimidine antagonist, and can
manifests as angina pectons, myocardial infarction, cardio-
genic shock, arrythmias and death [I]. Clinical evidence of
5-FU cardiotoxicity is generally considered to occur in about
2% of treated patients, probably more often in those with
known coronary disease and previous radiotherapy. Patients
have been reported to develop typical clinical and electro-
graphic manifestations within a few hours of initiating the
infusion to up to 18 hours after its completion. Symptoms and
ECG signs are known to subside at drug cessation, while
continuation of the drug has been associated with myocardial
infarction, pulmonary oedema and even death. Recurrence of
typical chest pain was observed with 5-FU rechallenge. Coro-
nary spasm is postulated to account for this cardiotoxicity [1,2]
though other mechanisms have been proposed [2].
Capecitabine is a fluoropyrimidine which after oral admin-
istration is metabolized into 5-FU by thymidine phosphorylase.
Since the metabolizing enzyme appears to be preferentially
expressed by tumor cells, capecitabine is considered to exert a
selective antitumoral action.
A recent randomized phase II study performed in 109
colorectal cancer patients reported 5 cases (4.5%) of probable
cardiac toxicity, including 4 patients with chest pain [3]. The
pain began four to eight days after initiation of treatment and
resolved with interruption of therapy. In two cases, rechallenge
with the drug was associated with pain relapse. ECG changes
were not reported in the article and no coronary angiogram
was performed. In the same article [3] preliminary data from
2 pooled randomized phase III studies performed in 596 patients
are mentioned (Van Cutsem E et al., manuscript in preparation):
2% cardiac events were observed in the capecitabin arm versus
1.3% in the 5-FU-leucovorin arm.
To our knowledge, no coronary spasm documented by
coronary angiogram and secondary to capecitabin has yet
been reported. We believe that our clinical observation should
remind physicians about the potential coronary toxicity of
capecitabine. Clinical and ECG manifestations of angina
should prompt drug discontinuation.
B. Schnetzler,1 N. Popova,1 C. Collao Lamb 2 &
A. P. Sappino 2
Divisions de ]Cardiologie, 2Oncologie, Hopitaux Univer-
sitaires de Geneve, Geneve, Switzerland
References
1 Anand AJ. Fluorouracil cardiolo.xicity. Ann Pharmacother 1994.
28- 374-8.
2. Luwaert RJ, Descamps O. Majois F et al. Coronary artery spasm
induced by 5-fluorouracil. Eur Heart J 1991; 12: 468-70.
3 Van Cutsem E. Findlay M, Osterwalder B et al. Capecitabine,
an oral fluoropyrimidine carbamate with substantial activity in
advanced colorectal cancer: Results of a randomized phase II
study. J Clin Oncol 2000; 18: 1337-45.
Bone scan had no role in the staging
of 765 consecutive operable T1_2N0_i
breast cancer patients without
skeletal symptoms
Bone scanning (BS) is considered a sensitive test for the detec-
tion of metastatic breast cancer [1-3], but not all abnormal
findings on bone scan are diagnostic of skeletal metastasis. For
this reason, the role of BS in the staging of breast cancer has
been widely questioned in recent years [4—7]. Recent studies
have found a relatively low rate (less than or equal to 5%) of
abnormal scans in patients with stage I and II breast cancers,
and only half of those with positive scans subsequently had
documented bony metastasis [2]. Despite these data bone scan
continues to be prescribed during staging, and there was never
an intention to question the role of 'staging' bone scan imme-
diately after diagnosis and operation. The aim of this report
was to ascertain the relevance of bone scan (BS) in detecting
asymptomatic bone metastases in the preoperative staging of
disease in a group of patients studied by the same team of
physicians in a very short recruitment time. No previous study
reported our number of patients studied by the same team in
so short a recruitment time.
A retrospective review of 765 consecutive patients with
operable breast cancer staged according to the TNM staging
system asT|_2 , No_, and all referred to the European Institute
of Oncology (EIO) between April 1997 and January 2000, was
performed. No selection criteria have been used in our cohort.
Patients had a histologically proven breast cancer and had
definitive breast surgery and staging preoperative bone scan at
the EIO. All bone scans were performed and evaluated by the
same team of physicians at the Division of Nuclear Medicine.
Whole body scintigraphy was obtained three hours after in-
jection of 740 MBq of Technetium 99m-labeled methylene
diphosphonate in anterior and posterior projections by use of
a large-field gamma camera (GE MAXXUS) equipped with a
HR low energy collimator. Stage of disease was defined by
standard pathological examination techniques.
All patients were asymptomatic at the time of BS. Patient
characteristics are displayed in Table I. Increased uptake of
uncertain dignity was observed in 40 (5%) patients and
attributed, in differential diagnosis, to degenerative bone ab-
normalities or compression fractures of vertebrae. Detected
'hot spots' were investigated with the same type of radiologic
examination. An algorithm that provided X-ray and CT scan
Table I Major patient characteristics
Total
T,N0
T,N,
T2N0
T2N,
ER/PgR positive"
Grade 1
Grade 2
Grade 3
Grade nd
" ER and/or PgR :
Number of patients
765
261
237
109
158
652
126
354
274
II
> 10% of the cells or 10 fmoles.
True positive (%)
4(0.5)
-
1 (0 4)
-
3(2)
3(0 4)
3(0 8)
1(0 3)
-
